Ultomiris shows strong interim results in Phase III IgA nephropathy trial

IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys

HCL Healthcare opens Bengaluru office to deepen enterprise client engagement

New regional hub strengthens presence in a key market and enhances service delivery for corporate healthcare clients

New guardian protein mechanism identified in aggressive skin cancer progression

While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies

ECI taps industry veteran Khalid Raja to drive strategic growth

Move comes amid rising regulatory pressures

US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Pfizer unleashes wave of breakthrough cancer data at ASCO 2026

Pharma giant targets new standards of care

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Asahi Kasei pushes into human trials with new autoimmune drug candidate

The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp

Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push

The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform

Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease

By cutting pain crises & boosting haemoglobin